The agency previously had granted the drug, called Leqembi, accelerated approval based on its ability to reduce amyloid clumps in the brain, a hallmark of Alzheimer’s.
More than 11 million caregivers in the United States provide unpaid care for loved ones with dementia, and millions more care for parents or aging loved ones with other health challenges.
Local experts said the policy change is a step in the right direction for reducing weight stigma and pushing research toward a more comprehensive direction.
Something went wrong. Please try again in a few minutes. If the problem persists, please contact customer service at 800-228-6397 or pgsupport@post-gazette.com.